Saturday, 30 August 2014

Pintapro ® XR Cinitapride HYDROGEN TARTRATE EXTENDED RELEASE CAPSULES, For the treatment of gastroesophageal reflux disease ...

Pintapro ® XR Cinitapride HYDROGEN TARTRATE EXTENDED RELEASE CAPSULES








Pintapro ® Cinitapride  is a gastroprokinetic agent and antiulcer agent of the benzamide class
which is marketed in India, Mexico, Pakistan and Spain. It acts as an agonist of the 5-HT1
and 5-HT4 receptors and as an antagonist of the 5-HT2 receptors.

Pintapro ® (Cinitapride) is a antiemetic medication prescribed to treat conditions caused by an overactive digestive tract.
It slows the actions of the muscles to reduce the symptoms of conditions such as acid reflux, ulcer dyspepsia, and delayed gastric emptying.
Uses : Pintapro ® (Cinitapride) is a antiemetic medication prescribed to treat conditions caused by an overactive digestive tract.
It slows the actions of the muscles to reduce the symptoms of conditions such as acid reflux, ulcer dyspepsia, and delayed gastric emptying.
Your doctor may also prescribe it to treat other conditions that are not listed here.

Pintapro ® Cinitapride  prescribed to treat conditions
 caused by an overactive digestive tract.

Important Notice: The blogger.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

The authors are thankful M/S Taj Pharmaceuticals Limited, Vapi, Gujarat
(India) and Knis Laboratories, Chennai, TN (India) for providing
Cinitapride and pantoprazole as gift samples respectively. The
authors are also thankful to the Department of Pharmaceutical
Chemistry, College of Pharmacy, Madras Medical College for
rendering full support to carry out the study.







www.tajpharma.com

No.F. l/Acad/MC/SEP/O9/ 11 L/ Dated. 45


REFERENCES
1. Roberts DJ. The pharmacological basis of the therapeutic
activity of clebopride and related substituted benzamides. Curr
Ther Res . 1982; 31: S1–S44.
2. Fernandez AG and Roberts DJ Cinitapride hydrogen tartrate.
Drugs Fut. 1991; 16: 885–892.
3. www.cipladoc.com
4. Graham L. Patrick. An Introduction to Medicinal Chemistry. 4th
ed. Oxford University Press; 2010; 674.
5. Paresh U. Patel, Shivang K. Prabtani. First Derivative
Spectrophotometric Method for Simultaneous Estimation of
Pantoprazole and Cinitapride in Combined Dosage Form. Int J
of Pharm Research, 2011; 3 (2): 53-54.
6. Patel GH, Prajapati ST, Patel CN. HPTLC method development
and validation for simultaneous determination of cinitapride
and pantoprazole in capsule dosage form. Research J of Pharm
and Tech. 2011; 4 (9): 1428-1431.
7. www.drugbank.com
8. Shahar Yar M. Pharmaceutical Analysis: Methods of Analysis
and Assay: Miscellaneous Methods of analysis. Available from:
URL: nsdl.niscair.res.in/revised +miscellaneous+method+of+
analysis.pdf/2007
9. www.chemguide.co.uk. 2007: Jim Clark. Making of diazonium
salts from phenyl amine.
10. Chand Pasha, Narayana B. A simple spectrophotometric
method for the determination of mosapride by diazotization
method. Yanbu Journal of Engineering and Science 2010;
1(143H): 68-73.
11. Willard H, Lynne Merritt, John A Dean,Frank A Seattle.
Instrumental methods of Analysis. 6th ed.
12. Adnan A Badwan, Lina N. Nebulas, AI Olnflri MM, Nidal H.
Daraghmeh, Mahmoud K. Shour, Abroad M. Abdoh I, Jaber AMY
Analytical profiles of drug substances and excipients 2002; 29
p.213
 New Delhi: 1986; p
67-68
13. Vogels Qualitative Inorganic Analysis. 7 th ed. New Delhi:
Dorling Kindersely India (pvt) Ltd: 2007. p. 124,128.












No comments:

Post a Comment